CCK (Cholecystokinin): A Six-Module Literature Course

This page is a six-module reading guide to the published literature on cholecystokinin (CCK). It describes what the cited papers examined, in which models, and what their authors reported. It does not recommend use, describe protocols, or promise outcomes. This page is for educational purposes only and is not medical advice; consult a licensed physician for any questions about health, medications, or research participation.

A note on the shape of this evidence base: the verified studies summarised here were conducted in fish, shrews, rats, mice, and human tumour tissue or cells. Findings in those systems describe those systems. Each module closes with an explicit statement of what the evidence does not establish.

Module 1 — What CCK Is and How It Has Been Studied

Definition and class

Cholecystokinin is a peptide hormone and neuropeptide of the gastrin/CCK family. It is classed as a gut–brain signalling peptide: it is released from the intestinal mucosa and is also expressed in central and peripheral neurons. Reviews of the central system describe CCK as one of the more widely distributed neuropeptides in the mammalian brain, co-expressed with classical neurotransmitters in circuits relevant to reward and motivation, as summarised in a 2022 review of CCK neural circuit mechanisms in addiction (PMID 35983578).

Origin: where the peptide is made

In the intestine, CCK is produced by enteroendocrine cells. A 2017 mouse study mapped these cells and reported that CCK-containing enteroendocrine cells were distributed through the small intestine and were also present in the large intestine, and that many of them co-stored other gut hormones rather than CCK alone (PMID 28413860). That mapping work is frequently used as the anatomical basis for describing CCK as a nutrient-responsive intestinal signal.

Forms and species conservation

CCK circulates as several molecular forms generated from a single precursor, commonly named by length — CCK-8, CCK-33, CCK-58 among them. The distinction between forms is not cosmetic: a 2012 rat study compared CCK-8 and CCK-58 directly and reported that the two forms differed in their effects on nocturnal solid meal patterns in undisturbed animals (PMID 22874423).

The peptide is evolutionarily old. Researchers cloned CCK and the CCK-A receptor in the house musk shrew (Suncus murinus) and characterised the receptor's role in gastrointestinal motility (PMID 35700795), while separate work examined CCK in largemouth bass feeding regulation (PMID 39194573) and in the gut of the stomachless ballan wrasse (PMID 31231179).

Limits of the evidence in Module 1

Anatomical mapping and cloning studies describe where a peptide and its receptors are present; they do not establish clinical significance. The mouse distribution study characterised cells in mice (PMID 28413860), and fish and shrew studies describe those species. None of these papers measured human physiological or therapeutic endpoints.

Module 2 — Mechanism as Described in the Literature

Two receptor subtypes

The literature describes CCK acting at two G-protein-coupled receptors, CCK-A (CCK1) and CCK-B (CCK2, also the gastrin receptor). The 2022 shrew study cloned the CCK-A receptor and reported that CCK-8-induced gastrointestinal motility in Suncus murinus was mediated through that receptor, with the response examined using receptor-selective pharmacology (PMID 35700795).

Antagonist logic in feeding studies

The standard way researchers test whether an observed effect is receptor-mediated is to block the receptor. The 2024 largemouth bass study followed that design — peptide activation paired with antagonist inhibition — and reported that CCK administration suppressed feeding behaviour while antagonist treatment opposed that suppression, which the authors interpreted as receptor-dependent feeding regulation (PMID 39194573).

Gut motility and the enteric nervous system

Mechanistic gut work looks at smooth muscle and enteric nerves. In the stomachless ballan wrasse, researchers reported that CCK altered contractile activity in gut preparations, with responses differing between gut regions, indicating region-specific motility effects in a species that lacks a stomach (PMID 31231179). The shrew work similarly framed CCK-8 as a motility-modulating signal acting via CCK-A receptors along the gastrointestinal tract (PMID 35700795).

Peripheral non-gut targets

Mechanistic interest extends beyond the gut. A 2019 study in British Journal of Pharmacology reported that the CCK receptor agonist CCK-8 induced adiponectin production in rat white adipose tissue, identifying adipose tissue as a CCK-responsive compartment (PMID 31012948). In human tumour tissue, a 2005 study reported that meningiomas expressed CCK and responded to CCK exposure, which the authors discussed as evidence of a functional receptor system in that tumour type (PMID 15980969).

Central circuits

The 2022 review described CCK signalling within specific neural circuits — including co-expression with other transmitters in reward-related pathways — and framed the CCK system as a modulator relevant to addiction-related behaviour rather than a direct effector (PMID 35983578).

Limits of the evidence in Module 2

Mechanistic plausibility is not clinical effect. Receptor-blockade experiments in fish (PMID 39194573) and receptor cloning in shrews (PMID 35700795) explain how a signal may operate in those animals. A narrative review summarises circuit models (PMID 35983578) but does not itself generate outcome data.

Module 3 — Reported Outcomes, Study by Study

The table below lists the models, endpoints, and reported directions of effect from the verified literature. No doses are given where the verified sources do not place them within abstract-level scope.

Reading the pattern

Two themes recur. First, short-term ingestive and motility signalling: feeding suppression in fish (PMID 39194573), meal-pattern changes in rats (PMID 22874423), and motility changes in wrasse and shrew preparations (PMID 31231179, PMID 35700795). Second, effects outside the gut: adipose signalling (PMID 31012948) and tumour tissue responsiveness (PMID 15980969).

Limits of the evidence in Module 3

These are single studies in different species with different endpoints; they were not designed to be pooled. None reported human clinical outcomes such as body weight over time, symptom scores, or quality-of-life measures. Directional findings in fish and rodents do not predict human responses, and the meningioma work described tissue biology rather than treatment results (PMID 15980969).

Module 4 — CCK Side Effects: What Studies Report

The verified literature on CCK is preclinical and mechanistic. These papers generally did not run tolerability or safety endpoints, so what follows is a description of the physiological changes researchers reported, not a safety profile.

Gastrointestinal changes

The clearest reported changes are gastrointestinal. In the stomachless ballan wrasse, researchers reported altered contractile activity in gut segments following CCK exposure, with regional differences in responsiveness (PMID 31231179). In Suncus murinus, the study reported CCK-8-induced gastrointestinal motility acting through the CCK-A receptor (PMID 35700795). Motility modulation is the intended pharmacological action in those designs; whether comparable changes would be experienced as adverse in another species was not assessed.

Feeding and meal-pattern changes

Suppression of feed intake was an endpoint, not an adverse event, in the largemouth bass study, where researchers reported reduced feeding after CCK administration and inhibition of that effect by an antagonist (PMID 39194573). In rats, the study reported that CCK-8 and CCK-58 produced different nocturnal meal patterns, showing that the direction and shape of ingestive change depended on which molecular form was administered (PMID 22874423).

Findings relevant to proliferation and behaviour

Two further findings are frequently raised in discussions of CCK biology. The 2005 study reported that meningiomas expressed CCK and responded to it, a tissue-level observation about a tumour type rather than a reported adverse event in a treated subject (PMID 15980969). The 2022 review described CCK circuit involvement in addiction-related behaviour, framing the peptide as a modulator within reward pathways (PMID 35983578).

Limits of the evidence in Module 4

No verified study here reported graded adverse-event tables, withdrawal rates, laboratory abnormalities, or long-term safety follow-up. Absence of reported adverse events in animal mechanistic work is not evidence of safety in humans, and none of these papers examined repeated or prolonged administration in people.

Module 5 — Pharmacokinetics Where Data Exist

The verified literature contains no human pharmacokinetic dataset — no reported half-life, clearance, volume of distribution, or bioavailability values. What it does contain is indirect evidence that molecular form matters. The 2012 rat study compared CCK-8 with CCK-58 on nocturnal solid meal patterns and reported that the two forms behaved differently, a result the authors discussed in terms of the forms not being interchangeable (PMID 22874423).

Route and target-tissue considerations

Because CCK is a peptide, the cited work used parenteral administration or direct tissue exposure rather than oral dosing. Receptor-level studies define where an administered peptide can act: the shrew study cloned the CCK-A receptor and linked CCK-8 exposure to motility responses in gastrointestinal tissue (PMID 35700795), and the rat adipose study reported that CCK-8 induced adiponectin production in white adipose tissue, implying access to that tissue under the study's conditions (PMID 31012948).

Limits of the evidence in Module 5

No pharmacokinetic parameters are reported in these papers, so any half-life or exposure figure quoted elsewhere cannot be sourced to this evidence base. Cross-species extrapolation is particularly weak for peptides, and endogenous CCK kinetics after a meal are a different question from the kinetics of an administered analogue.

Module 6 — Regulatory Status, Stated Factually

The following is a general description of regulatory categories and is not legal advice.

• Approved diagnostic use. A synthetic CCK-8 analogue, sincalide, has been marketed in the United States as a prescription diagnostic agent used in gallbladder and pancreatic function imaging procedures. Where such a product exists, its labelling, indication, and administration are determined by the approving regulator and the product label, not by research literature.
• Research-use-only material. CCK peptides such as CCK-8 and CCK-58 are widely supplied as research chemicals for laboratory work. Research-use-only labelling means a material has not been evaluated or authorised as a drug for human administration, and it is not a claim of safety or effectiveness.
• Compounding. In the United States, compounded preparations are made by licensed pharmacies under specific statutory conditions and, unlike approved drugs, are not individually reviewed for safety, effectiveness, or manufacturing quality before distribution. Whether any particular peptide may lawfully be compounded depends on ingredient eligibility rules and agency determinations that change over time.
• Research context of the cited studies. The verified papers were conducted as animal, tissue, or cell research — for example the fish feeding study (PMID 39194573) and the mouse intestinal mapping study (PMID 28413860) — and none of them constitute a regulatory approval pathway.

Limits of the evidence in Module 6

Regulatory status varies by country and changes without reference to the scientific literature. An approved diagnostic indication for one CCK analogue says nothing about the status of other forms, other routes, or other purposes, and none of the cited studies addressed regulatory questions.

Closing: What the Studies Did Not Test

Read together, the verified literature leaves large gaps:

1. Human outcome trials. No cited study reported randomised human results for appetite, body weight, metabolic markers, or gastrointestinal symptoms.
2. Long-term administration. The work described short-term or acute exposures; no cited paper reported months-long dosing or follow-up.
3. Dose–response in humans. Fish, shrew, and rat studies reported effects in their own models (PMID 39194573, PMID 35700795, PMID 22874423), not human dose–response curves.
4. Safety monitoring. None of the cited papers reported structured adverse-event collection or laboratory safety panels.
5. Combination use. No cited study examined CCK peptides alongside other agents.
6. Clinical relevance of tissue findings. The adipose and meningioma results describe tissue responses (PMID 31012948, PMID 15980969) and were not tests of any therapeutic application.

Anyone evaluating claims about CCK can usefully ask which of these six gaps a given claim depends on. Where the answer is "all of them", the claim is running ahead of the published evidence.

References

• Role of Cholecystokinin (CCK) in Feeding Regulation of Largemouth Bass (Micropterus salmoides): Peptide Activation and Antagonist Inhibition (Biology, 2024)
• Effects of Cholecystokinin (CCK) on Gut Motility in the Stomachless Fish Ballan Wrasse (Labrus bergylta) (Frontiers in Neuroscience, 2019)
• Neural circuit mechanisms of the cholecystokinin (CCK) neuropeptide system in addiction (Addiction Neuroscience, 2022)
• Distribution and characterisation of CCK containing enteroendocrine cells of the mouse small and large intestine (Cell and Tissue Research, 2017)
• Molecular cloning of cholecystokinin (CCK) and CCK-A receptor and mechanism of CCK-induced gastrointestinal motility in Suncus murinus (General and Comparative Endocrinology, 2022)
• Meningiomas expressing and responding to cholecystokinin (CCK) (Journal of Neuro-Oncology, 2005)
• The cholecystokinin receptor agonist, CCK-8, induces adiponectin production in rat white adipose tissue (British Journal of Pharmacology, 2019)
• CCK-8 and CCK-58 differ in their effects on nocturnal solid meal pattern in undisturbed rats (American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 2012)